

Overview of Scientific Presentations

HIV TREATMENT RESEARCH (B/F/TAF)	
Oral Presentation	Randomized, multicenter, double-blind clinical trial designed to evaluate the safety and convenience of switching from dolutegravir/lamivudine to bicitegravir/emtricitabine/tenofovir alafenamide in people with HIV, good virologic control and neuropsychiatric comorbidities: Week 24 results from the MIND Study.
Poster	Four-year outcomes from the BICSTaR study: Observational analysis of bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve (TN) and treatment-experienced (TE) people with HIV in Canada, France and Germany
Poster	Bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve people with both HIV-1 and hepatitis B: 3-year outcomes from ALLIANCE
Poster	Global survey to evaluate engagement in care and treatment experiences of people with HIV
Poster	Rapid Start (RS) with bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with HIV-1 (PWH): A systematic literature review (SLR) of clinical and patient-reported outcomes (PROs)
Poster	Persistence, safety, and virologic outcomes of B/F/TAF as a baseline or switch regimen in HIV-infected people living with advanced HIV disease in the real world: the BIC-CD4 study.
Poster	Real-world effectiveness in treatment-experienced (TE) people with HIV (PWH) switching to bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) with distinct patterns of self-reported adherence
Poster	Multicentre, prospective cohort study of same-day initiation of antiretroviral therapy with BIC/FTC/TAF among antiretroviral-naïve people with HIV
Poster	Real-World Persistence of Bicitegravir- versus Dolutegravir-based Single Tablet Regimens in a Large Urban Canadian HIV Centre
Poster	Incidence of comorbidities over 18 months with BIC/FTC/TAF, DTG/ABC/3TC or DTG/3TC in real life settings in the ANRS-CO3 - AquIVIH-NA cohort.
Poster	Effectiveness of switching to B/F/TAF in virologically suppressed people with HIV and with preexisting resistance-associated mutations in Italy: the BIC-BARRIER Study
Poster	Evaluation of T-cell immunosenescence in +60 years PLWH virologically suppressed on 3DR with BIC/FTC/TAF or 2DR with DTG/3TC: the Collateral-2 study.
LONG-ACTING HIV TREATMENT & PREVENTION RESEARCH (LENACAPAVIR)	
Oral Presentation (late breaker)	Once-Weekly Islatravir Plus Lenacapavir in Virologically Suppressed PWH: Week 48 Safety, Efficacy, and Metabolic Changes
Oral Presentation (late breaker)	Persistence in use of twice-yearly lenacapavir versus daily oral PrEP in the PURPOSE 1 Phase 3 trial
Oral Presentation (late breaker)	Twice-yearly lenacapavir PrEP in cisgender gay men, transgender women and men, and gender-diverse people (PURPOSE 2)

Poster	Pharmacokinetic/Pharmacodynamic and Resistance Analyses of GS-1720, a Once-Weekly Oral Integrase Strand Transfer Inhibitor
Poster	Pharmacokinetics of oral islatravir (ISL) plus lenacapavir (LEN) given once weekly in an open-label, active-controlled, phase 2 study of virologically suppressed people with HIV
HIV TREATMENT PIPELINE RESEARCH	
Oral Presentation	Efficacy and safety analysis of lenacapavir with broadly neutralising antibodies, teropavimab and znlirvimab, in people with HIV-1 highly sensitive to one or both broadly neutralising antibodies
Poster	Pharmacokinetic (PK) analysis of oral once-daily bicitgravir (BIC) plus lenacapavir (LEN) administered separately (BIC 75mg + LEN 25mg; BIC 75mg + LEN 50mg) and as a single-tablet BIC/LEN 75/50mg fixed-dose combination (FDC) to support Phase 3 dose selection
Poster	Effect of acid reducing agents on the pharmacokinetics of oral GS-4182
Poster	Safety and immunogenicity of GS-1966+GS-1144 vaccines in virally suppressed adults living with HIV-1: a phase 1b, randomised, placebo-controlled study
Poster	Metabolic changes at 48 weeks in virologically suppressed people with HIV switching from complex antiretroviral regimens to bicitgravir plus lenacapavir: ARTISTRY-1 trial
HIV PREVENTION RESEARCH	
Poster	Estimating return on investment (ROI) with increased utilisation of HIV pre-exposure prophylaxis (PrEP) among key populations in France from a national health payer perspective
Poster	PrEP cascade improvement through same-day PrEP initiation
Poster	Prevalence of HIV drug resistance in people newly diagnosed with HIV who have used Pre-exposure Prophylaxis in Europe; the PrEPaRe study.
Poster	HIV-1 prevalence and pre-exposure prophylaxis uptake among key populations in high-income economies (2017-2023): a systematic review and meta-analysis of real-world studies
ADDITIONAL HIV RESEARCH	
Oral Presentation (late breaker)	Clinical features and resistance patterns during second-generation INSTI failure: The ROSETTA-registry
Oral Presentation (late breaker)	Mortality using raltegravir versus other integrase inhibitors in people with HIV in Europe and Australia
Poster (late breaker)	Comparison of treatment-emergent resistance associated mutations among three-drug single tablet regimens and cabotegravir+rilpivirine for the treatment of virologically suppressed people with HIV: A Systematic Literature Review and Network Meta-Analysis
Poster (late breaker)	The prevalence and factors associated with polypharmacy in participants with HIV in the Pharmacokinetic and clinical Observations in PeoPle over fifty (POPPY) study over a 3-5 year period
Poster	Replication-competent HIV-1 harbouring resistance-associated mutations is present in the viral reservoir
Poster	Treatment Patterns in Virologically Suppressed, Treatment-Experienced People with HIV; a US Real-World Database Study

Poster	Demographic and clinical characteristics of treatment naïve people with HIV, and their healthcare professionals' reasons for treatment choice: findings from a real-world survey in five European countries
Poster	Understanding knowledge and attitudes regarding HIV amongst secondary care healthcare professionals in the United Kingdom: A national survey
Poster	The association between anticholinergic medication use and cognitive function in older people with HIV in the Pharmacokinetic and clinical Observations in PeoPle over fifty (POPPY) Study

For more information about Gilead at HIV Glasgow 2024, including a complete list of abstracts and their corresponding oral and poster sessions, please visit <https://hivglasgow.org/programme/>.

The use of lenacapavir for the prevention of HIV is investigational and has not been determined to be safe or efficacious and is not approved anywhere globally.